The cervical dystonia therapeutics market share is expected to increase to USD 154.77 million from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 5.43%.
This cervical dystonia therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cervical dystonia therapeutics market segmentation by the follwing:
- Product - Botulinum toxins and other therapeutics
- Geography (North America, Europe, Asia, and ROW
The cervical dystonia therapeutics market report also offers information on several market vendors, including AbbVie Inc., Akorn Inc., Eisai Co. Ltd., Galderma SA, Ipsen Pharma, Lannett Co. Inc., Medytox Inc., Merz Pharma GmbH, and Co. KGaA, Revance Therapeutics Inc., and Supernus Pharmaceuticals Inc. among others.
What will the Cervical Dystonia Therapeutics Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Cervical Dystonia Therapeutics Market Size for the Forecast Period and Other Important Statistics
Cervical Dystonia Therapeutics Market: Key Drivers, Trends, and Challenges
The expected approval of late-stage pipeline molecules is notably driving the cervical dystonia therapeutics market growth, although factors such as the availability of alternative therapies may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cervical dystonia therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Cervical Dystonia Therapeutics Market Driver
The expected approval of late-stage pipeline molecules is one of the key drivers supporting cervical dystonia therapeutics market growth. Despite the significant research undertaken over the past several decades, a treatment that is promising and has fewer side effects is not yet available for cervical dystonia. This is encouraging pharmaceutical companies to focus on the development of promising therapeutics for the treatment of cervical dystonia. For instance, Revance Therapeutics commenced an open-label, multi-center Phase III trial to evaluate the long-term safety and efficacy of repeat treatments of daxibotulinumtoxinA in adults who have isolated cervical dystonia, which was completed in January 2021. The company received approval from the US FDA in April 2021. Once these molecules are launched during the forecast period, the global cervical dystonia therapeutics market should witness strong value growth from these newly launched therapeutics.
Key Cervical Dystonia Therapeutics Market Trend
The reimbursement for botulinum neurotoxin injections is another factor supporting cervical dystonia therapeutics market growth. Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia. These reimbursement programs help patients with or without medical insurance to achieve appropriate reimbursement for their treatment with botulinum toxins. For instance, ALLERGAN, the manufacturer of BOTOX, sponsors a comprehensive reimbursement program called as BOTOX Reimbursement Solutions Program. This program includes a BOTOX Hotline and BOTOX Patient Assistance Program to assist patients who are receiving BOTOX injection treatment. The BOTOX Patient Assistance Program helps financially eligible patients gain access to BOTOX. Thus, several reimbursement programs aid the eligible patients for the high-cost botulinum toxins treatment and boost the global cervical dystonia market growth over the forecast period.
Key Cervical Dystonia Therapeutics Market Challenge
The availability of alternative therapies may hinder the cervical dystonia therapeutics market growth during the forecast period. For the treatment of cervical dystonia, botulinum toxins and other therapeutics are mainly used. However, the low success rate and temporary cure of these therapeutics lead people to prefer alternative therapies such as DBS surgery. It is a highly effective procedure for cervical dystonia and is appropriate for patients who stop showing a response to botulinum toxin. The sensory trick is another option available for the treatment of cervical dystonia. The key to treatment is to get it addressed as soon as possible to avoid the progress of cervical dystonia symptoms. Hence, the available alternative treatments are expected to strongly hamper the growth of the cervical dystonia therapeutics market over the forecast period.
This cervical dystonia therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Parent Market Analysis
Technavio categorizes the cervical dystonia therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cervical dystonia therapeutics market during the forecast period.
Who are the Major Cervical Dystonia Therapeutics Market Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- AbbVie Inc.
- Akorn Inc.
- Eisai Co. Ltd.
- Galderma SA
- Ipsen Pharma
- Lannett Co. Inc.
- Medytox Inc.
- Merz Pharma GmbH and Co. KGaA
- Revance Therapeutics Inc.
- Supernus Pharmaceuticals Inc.
This statistical study of the cervical dystonia therapeutics market encompasses successful business strategies deployed by the key vendors. The cervical dystonia therapeutics market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Product Insights and News
- AbbVie Inc. - The company offers cervical dystonia therapeutics namely BOTOX through its subsidiary Allergan Inc.
- AbbVie Inc. - Under the unified segment, the company conducts research and development, manufacturing, commercialization and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long term strategic goals.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The cervical dystonia therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Cervical Dystonia Therapeutics Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the cervical dystonia therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
- Research and development (R&D) and drug discovery
- Integration and product development
- Manufacturing
- Outbound logistics
- Marketing and sales
- Support services
- Innovation
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
Which are the Key Regions for Cervical Dystonia Therapeutics Market?
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the cervical dystonia therapeutics market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The presence of the highest adult population will facilitate the cervical dystonia therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, countries such as the US and Canada in North America were severely affected by the COVID-19 pandemic. The rise in the incidence of COVID-19 across various countries in North America influenced governments to introduce emergency legislation, which included restrictions on several business activities. This led to the shutdown of manufacturing units of several industries in 2020. A few essential industries, such as pharmaceutical companies, were allowed to operate at the usual utilization rate. However, as most of these pharmaceutical companies also focused on developing COVID-19 vaccines and manufacturing other drugs to support the medical crisis associated with the COVID-19 pandemic, the production volume of therapeutic drugs other than COVID-19 declined to a certain extent during the first few months of 2020.
What are the Revenue-generating Product Segments in the Cervical Dystonia Therapeutics Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The cervical dystonia therapeutics market share growth by the botulinum toxins segment will be significant during the forecast period. The growth of the botulinum toxins segment is primarily driven by the increasing usage of botulinum toxins A and B for the treatment of cervical dystonia. For instance, currently, MEDITOXIN and daxibotulinumtoxinA are in the Phase III stage of development for the treatment of cervical dystonia and are expected to enter into the market and generate significant revenue during the forecast period. This, in turn, will enhance the growth of the global cervical dystonia therapeutics market over the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the cervical dystonia therapeutics market size and actionable market insights on post COVID-19 impact on each segment.
|
Cervical Dystonia Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.43% |
|
Market growth 2021-2025 |
$ 154.77 million |
|
Market structure |
Concentrated |
|
YoY growth (%) |
4.15 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 38% |
|
Key consumer countries |
US, Canada, Germany, China, and UK |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
AbbVie Inc., Akorn Inc., Eisai Co. Ltd., Galderma SA, Ipsen Pharma, Lannett Co. Inc., Medytox Inc., Merz Pharma GmbH and Co. KGaA, Revance Therapeutics Inc., and Supernus Pharmaceuticals Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Cervical Dystonia Therapeutics Market Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive cervical dystonia therapeutics market growth during the next five years
- Precise estimation of the cervical dystonia therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the cervical dystonia therapeutics industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of cervical dystonia therapeutics market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch